Abstract
Purpose: A prospective, double-blind study was conducted to compare the clinical efficacy of a combination of 1% tropicamide and 2.5% phenylephrine and a combination of 1% tropicamide and 10% phenylephrine for pupillary dilation in patients with diabetes. Methods: Either 2.5% phenylephrine in one eye and 10% phenylephrine in the other eye, 2.5% phenylephrine in both eyes, or 10% phenylephrine in both eyes was administered to 127 consecutive patients with diabetes. All patients received 1% tropicamide in both eyes. Results: There was no statistically significant difference in the amount of pupillary dilation between the three groups. Conclusion: As 2.5% phenylephrine may produce a lower incidence of side effects than the 10% concentration, we advise the use of the lower concentration, particularly among patients with diabetes, who already exhibit a higher prevalence of vascular disease and autonomic dysfunction.
| Original language | English |
|---|---|
| Pages (from-to) | 130-133 |
| Number of pages | 4 |
| Journal | Retina |
| Volume | 15 |
| Issue number | 2 |
| State | Published - May 8 1995 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
- Sensory Systems
Cite this
The effects of phenylephrine 2.5% versus phenylephrine 10% on pupillary dilation in patients with diabetes. / Weiss, J. S.; Weiss, J. N.; Greenfield, David.
In: Retina, Vol. 15, No. 2, 08.05.1995, p. 130-133.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effects of phenylephrine 2.5% versus phenylephrine 10% on pupillary dilation in patients with diabetes
AU - Weiss, J. S.
AU - Weiss, J. N.
AU - Greenfield, David
PY - 1995/5/8
Y1 - 1995/5/8
N2 - Purpose: A prospective, double-blind study was conducted to compare the clinical efficacy of a combination of 1% tropicamide and 2.5% phenylephrine and a combination of 1% tropicamide and 10% phenylephrine for pupillary dilation in patients with diabetes. Methods: Either 2.5% phenylephrine in one eye and 10% phenylephrine in the other eye, 2.5% phenylephrine in both eyes, or 10% phenylephrine in both eyes was administered to 127 consecutive patients with diabetes. All patients received 1% tropicamide in both eyes. Results: There was no statistically significant difference in the amount of pupillary dilation between the three groups. Conclusion: As 2.5% phenylephrine may produce a lower incidence of side effects than the 10% concentration, we advise the use of the lower concentration, particularly among patients with diabetes, who already exhibit a higher prevalence of vascular disease and autonomic dysfunction.
AB - Purpose: A prospective, double-blind study was conducted to compare the clinical efficacy of a combination of 1% tropicamide and 2.5% phenylephrine and a combination of 1% tropicamide and 10% phenylephrine for pupillary dilation in patients with diabetes. Methods: Either 2.5% phenylephrine in one eye and 10% phenylephrine in the other eye, 2.5% phenylephrine in both eyes, or 10% phenylephrine in both eyes was administered to 127 consecutive patients with diabetes. All patients received 1% tropicamide in both eyes. Results: There was no statistically significant difference in the amount of pupillary dilation between the three groups. Conclusion: As 2.5% phenylephrine may produce a lower incidence of side effects than the 10% concentration, we advise the use of the lower concentration, particularly among patients with diabetes, who already exhibit a higher prevalence of vascular disease and autonomic dysfunction.
UR - http://www.scopus.com/inward/record.url?scp=0028959685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028959685&partnerID=8YFLogxK
M3 - Article
VL - 15
SP - 130
EP - 133
JO - Retina
JF - Retina
SN - 0275-004X
IS - 2
ER -